Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction

Abstract

BackgroundEarly inflammation following acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) affects myocardial infarct (MI) size and left ventricular remodeling. The mammalian target of rapamycin (mTOR) is involved in the enhanced inflammatory response and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI. ObjectivesThe CLEVER-ACS (Controlled Level Everolimus in Acute Coronary Syndromes) trial evaluated the effects of targeting inflammation by mTOR inhibition in patients with STEMI undergoing PCI. MethodsCLEVER-ACS was a randomized, multicenter, international, double-blind, placebo-controlled trial. A total of 150 patients with STEMI undergoing PCI were randomly assigned to oral everolimus (days 1-3: 7.5 mg daily; days 4-5: 5.0 mg daily) or placebo for 5 days. The primary endpoint was the change in MI size. The secondary endpoint was the change in microvascular obstruction (MVO) from baseline (12 hours to 5 days after PCI) to 30 days as assessed by cardiac magnetic resonance imaging. ResultsThe changes in MI size from baseline to 30 days, the primary endpoint, were –14.2 g (95% CI: –17.4 to –11.1 g) and –12.3 g (95% CI: –16.0 to –8.7 g) in the everolimus and placebo groups (P = 0.99). Corresponding changes in MVO were –4.8 g (95% CI: –6.7 to –2.9 g) and –6.3 g (95% CI: –8.7 to –4.0 g) in the everolimus and placebo groups (P = 0.14). Adverse events did not differ between the study groups. ConclusionsAmong STEMI patients undergoing PCI, early mTOR inhibition with everolimus did not reduce MI size or MVO at 30 days. (CLEVER-ACS [Controlled Level Everolimus in Acute Coronary Syndromes; NCT01529554)